The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(3-((5-Methoxyquinolin-2-yl)amino)phenyl)-4-morpholino-3-(trifluoromethyl)benzamide ID: ALA4743339
PubChem CID: 156597426
Max Phase: Preclinical
Molecular Formula: C28H25F3N4O3
Molecular Weight: 522.53
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COc1cccc2nc(Nc3cccc(NC(=O)c4ccc(N5CCOCC5)c(C(F)(F)F)c4)c3)ccc12
Standard InChI: InChI=1S/C28H25F3N4O3/c1-37-25-7-3-6-23-21(25)9-11-26(34-23)32-19-4-2-5-20(17-19)33-27(36)18-8-10-24(22(16-18)28(29,30)31)35-12-14-38-15-13-35/h2-11,16-17H,12-15H2,1H3,(H,32,34)(H,33,36)
Standard InChI Key: UJDNEVXCAKHSDH-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 42 0 0 0 0 0 0 0 0999 V2000
26.5068 -18.0499 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.5057 -18.8773 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2205 -19.2901 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2187 -17.6372 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.9340 -18.0463 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.9348 -18.8731 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.6501 -19.2841 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.3652 -18.8693 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.3604 -18.0393 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.6445 -17.6321 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2157 -16.8123 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
27.9288 -16.3974 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.0788 -19.2830 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
30.7940 -18.8717 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5053 -19.2899 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2200 -18.8793 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2218 -18.0535 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5030 -17.6399 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.7913 -18.0529 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.9321 -19.2946 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
33.6483 -18.8851 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.3610 -19.3007 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.6518 -18.0602 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
34.3561 -20.1260 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.0679 -20.5415 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.7852 -20.1320 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.7860 -19.3027 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.0736 -18.8910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.4976 -18.8886 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.1968 -19.3595 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
36.4991 -20.5493 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.4890 -21.3732 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.1987 -21.7905 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.9195 -21.3844 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
37.9260 -20.5566 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2117 -20.1347 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.0851 -18.1742 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
36.9101 -18.1742 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 5 1 0
4 11 1 0
11 12 1 0
8 13 1 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 14 1 0
16 20 1 0
20 21 1 0
21 22 1 0
21 23 2 0
22 24 2 0
24 25 1 0
25 26 2 0
26 27 1 0
27 28 2 0
28 22 1 0
29 30 1 0
27 29 1 0
26 31 1 0
31 32 1 0
31 36 1 0
32 33 1 0
33 34 1 0
34 35 1 0
35 36 1 0
29 37 1 0
29 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 522.53Molecular Weight (Monoisotopic): 522.1879AlogP: 6.09#Rotatable Bonds: 6Polar Surface Area: 75.72Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 5.70CX LogP: 5.87CX LogD: 5.86Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.32Np Likeness Score: -1.57
References 1. El-Damasy AK,Haque MM,Park JW,Shin SC,Lee JS,EunKyeong Kim E,Keum G. (2020) 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments., 208 [PMID:32942186 ] [10.1016/j.ejmech.2020.112756 ]